Quantcast
Last updated on April 21, 2014 at 1:20 EDT

Latest Antidepressant Stories

2014-01-13 08:29:50

Co-Promotion to Extend Physician Awareness of the First and Only FDA-Approved, Non-Hormonal Treatment for Moderate to Severe Menopausal Hot Flashes MIAMI and NEW YORK, Jan. 13, 2014 /PRNewswire/ -- Noven Pharmaceuticals, Inc. today announced that it has entered into an agreement with Shionogi Inc. to co-promote Brisdelle(TM) (paroxetine) capsules, 7.5 mg. The agreement will help extend physician awareness of the first and only FDA-approved, non-hormonal treatment for moderate to severe...

2014-01-10 08:23:35

BOSTON, Jan. 10, 2014 /PRNewswire/ -- The National Institute of Mental Health has prioritized the development of a rapidly acting treatment for depression as a key research goal. As a result, NIMH created the Rapidly Acting Treatments for Treatment Resistant Depression (RAPID) program to identify and test promising antidepressant interventions. Tal Medical's LFMS technology was selected to be tested in the first trial as part of the RAPID program. Historically, depression treatments...

2014-01-09 16:25:45

EVANSTON, Ill., Jan. 9, 2014 /PRNewswire/ -- Naurex Inc. today announced that Norbert G. Riedel, Ph.D., long-term board member and newly-appointed president and chief executive officer of Naurex, will present at the 32(nd) Annual J.P. Morgan Healthcare Conference at 3 p.m. PST on Tuesday, January 14, 2014 at the Westin St. Francis Hotel in San Francisco. Dr. Riedel will provide an overview of the company and discuss its two clinical-stage rapid-acting antidepressant drug candidates,...

2014-01-08 08:28:22

- Former Baxter International Executive Takes Helm as Neuropharmaceutical Innovator Prepares for Late-Stage Trials of its Novel Mechanism NMDA Receptor Modulators - EVANSTON, Ill., Jan. 8, 2014 /PRNewswire/ -- Naurex Inc. today announced that Norbert G. Riedel, Ph.D., has been named president and chief executive officer effective January 1, 2014. Naurex's founding chief executive officer Derek Small will continue as a director of the company. Naurex is a biopharmaceutical company...

Antidepressant Ketamine Boosts Seratonin
2014-01-08 08:29:44

Rebekah Eliason for redOrbit.com – Your Universe Online A new study revealed that the drug ketamine, a potent anesthetic used in human and veterinary medicine and as an illegal recreational drug, is a potential candidate for fast treatment of depression for individuals who do not respond to other types of medications. From the RIKEN Center for Life Science Technologies in Japan, new research using PET imaging studies has demonstrated that ketamine increases the activity level of...

2014-01-06 08:26:38

SAO PAULO, Jan. 6, 2014 /PRNewswire/ -- moksha8, a leader in the commercialization of CNS medicines in Latin America, today announced that it has filed applications with the Brazilian regulatory authority, ANVISA, for approval of Viibryd® (vilazodone) for major depressive disorders and Colobreathe (colistimethate sodium) to treat lung infections in patients with cystic fibrosis. moksha8 and Forest Laboratories have also amended the strategic alliance they signed in 2012. Forest...

2013-12-22 23:02:24

National network of attorneys will continue to accept inquiries through New Year's Day about legal options to seek compensation over allegations that children suffered birth defects due to use of SSRIs during pregnancies. San Diego, CA (PRWEB) December 22, 2013 http://www.resource4thepeople.com/defectivedrugs/SSRI-Birth-Defects.html Resource4thePeople announced today that its national network of attorneys will be available over the upcoming holiday season to consumers inquiring about...

2013-12-12 08:31:06

Sundance Diagnostics and the Max Planck Institute of Psychiatry Agree on Global License for Commercialization BOULDER, Colo., Dec. 12, 2013 /PRNewswire/ -- Sundance Diagnostics announces they have entered into an exclusive, worldwide licensing agreement with the Max Planck Institute of Psychiatry, Munich, Germany, to expand the Institute's initial clinical validation of genetic markers and to commercialize a genetic test that predicts risk of suicide emerging from use of...

Scientists Discover Gene That May Predict Response To Antidepressants
2013-12-10 07:53:02

redOrbit Staff & Wire Reports - Your Universe Online Treating depression using selective serotonin reuptake inhibitors (SSRIs) is often a trial-and-error process, but new research appearing in the journal Translational Psychiatry lays the foundation for a new genetic test that could allow doctors to provide patients with a personalized treatment program. Researchers at Tel Aviv University (TAU) explained that SSRIs do not work for everyone, even though they are the most commonly...

2013-12-09 08:27:18

- Company to Host Conference Call on Monday, December 9, at 10:00 am Eastern Time to Discuss Trial Results - NEW YORK, Dec. 9, 2013 /PRNewswire/ -- Intra-Cellular Therapies, Inc. ("we," "ITI" or "the Company"), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, announced today positive topline results from the Company's randomized, placebo- and active-controlled Phase II clinical trial of its lead drug candidate,...